Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546648 | 0.90 | CYP2C9 (0.40) | CYP2C9TDP1CYP1A2L3MBTL1POLB | |
| SCHEMBL15548251 | 0.89 | CYP2C9 (0.38) | CYP2C9TDP1CYP1A2L3MBTL1POLB | |
| SCHEMBL15548081 | 0.87 | CYP2C9 (0.39) | CYP2C9TDP1CYP1A2L3MBTL1POLB | |
| SCHEMBL15546399 | 0.86 | CYP1A2 (0.38) | CYP2C9TDP1CYP1A2L3MBTL1POLB | |
| SCHEMBL25027704 | 0.83 | — | — | |
| SCHEMBL30193778 | 0.83 | — | — | |
| SCHEMBL30193795 | 0.82 | — | — | |
| SCHEMBL25027589 | 0.82 | — | — | |
| SCHEMBL9905017 | 0.82 | AR (0.37) | POLB | |
| SCHEMBL18053272 | 0.82 | TAS2R8 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | claimed |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | claimed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | claimed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | claimed |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-01-03 | — | — | US | claimed |
| US-10160730-B2 | Triazoles as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-12-25 | — | — | US | claimed |
| EP-3386506-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | Autifony Therapeutics Limited (GB) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | claimed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | claimed |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-118267386-A | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108472288-B | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| EP-2852589-A1 | TRIAZOLES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175215-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | CYP2C9 1027/4885TDP1 2296/4885CYP1A2 652/4885 |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | CYP2C9 1620/4885TDP1 3899/4885CYP1A2 1928/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | CYP2C9 1027/4885TDP1 2296/4885CYP1A2 652/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | CYP2C9 1027/4885TDP1 2296/4885CYP1A2 652/4885 |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | KCNN3, KCNA3, KCND3 | CYP2C9 1646/4885TDP1 4008/4885CYP1A2 1958/4885 |
| US-10160730-B2 | Triazoles as KV3 inhibitors | KCNA3, KCNN3, KCNK3 | CYP2C9 1027/4885TDP1 2296/4885CYP1A2 652/4885 |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | CYP2C9 1646/4885TDP1 4008/4885CYP1A2 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.